STINGINN, LCC

STINGINN focuses on harnessing the innate immune system to combat infectious disease, inflammation and cancer. The company was formed around the discoveries of Glen N. Barber and the STING-controlled innate immune pathway. STING is key cellular protein that regulates the production of cytokines required to fight microbial infection and to generate effective anti-tumor immunity. The STING signaling pathway also controls inflammatory responses that can cause many types of autoimmune disease. Controlling STING has enormous potential to help alleviate infectious disease, inflammation and cancer. STINGINN has developed a variety of immunotherapeutic strategies to help achieve these goals. For these discoveries, in 2020 Glen N. Barber received the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology and in 2021 was elected a Fellow of the Royal Society, London.